ESR1 and breast cancer: The luteolin’s inhibitory effect on the IGF-1-induced breast cancer cell growth turned out to be dependent on ER α since the knockdown of ER α decreased the inhibitory effects of this substance on the IGF-1-induced cell growth [86].